Apply for Funding

Product Development Platform

Current Open RFP

RFP Product Development Platform 2020-002

The GHIT Fund announces an investment opportunity for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects should be no more than two years in duration and may focus on a broad array of R&D activities, including:


- Lead optimization

- Preclinical Development (in-vivo studies, formulation development, chemistry and process validation)

- Clinical Development (Phase 1, 2, or 3 studies, manufacturing scale-up)

- Activities to support licensure and WHO prequalification


Scope for the RFP-PD-2020-002 is primarily focused on continuation programs, diagnostics programs, and programs beyond lead optimization (e.g. FIH and POC).


Interested applicants can find detailed information on the RFP and the Intent to Apply form below.


(The schedule is subject to change due to unforeseen circumstances.)

RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

June 15, 2020

Intent to Apply

No later than 10:00 am Tokyo time on July 29, 2020

*Applicants are encouraged to submit the ITA well in advance of the Full Proposal submission deadline shown below to secure sufficient time to prepare full proposal.


Submit via Editorial Manager® for Product Development Platform (


No later than 10:00 am Tokyo time on August 11, 2020

Submit questions to

Email Subject Line: GHIT-RFP-PD-2020-002_Questions

Full Proposal Due

No later than 10:00 am Tokyo time on August 17, 2020

Submit via Editorial Manager® for Product Development Platform (


Full Proposal templates

*Only eligible applicants will be invited to submit the full proposal and will receive a password to open the proposal templates below.

[Drug]  [Vaccine]  [Diagnostics]

Proposals Evaluation and Interview Processes

August - February 2021

Award Notification to All Applicants

February 2021

Investment Agreement Fully Executed (Awarded Proposals)

March 2021

|Investment Process



ITA Submission

Interested applicants must complete the Intent to Apply (ITA) form and submit this to the GHIT Fund via Editorial Manager®, an online document submission system dedicated for this funding program within an RFP-specified timeframe. Please note that ITA documents or Proposals that are not submitted through the above-mentioned system will not be accepted. An ITA form will be posted on the GHIT Fund website when the RFP is released.


Management Team

Eligibility Review

Applicants who successfully submit the ITA document will receive a confirmation email. GHIT Fund staff will then perform an initial partnership and scope eligibility assessment. Eligible applicants will receive a confirmation email with GHIT Fund Proposal, Timeline, and Budget templates to support proposal development. If the project does not meet the eligibility requirements, the applicant will be notified that the project as proposed is not eligible for consideration. Applicants can remedy any eligibility issues and resubmit an ITA form up until the RFP-designated due date.



Full Proposal Submission

Applicants are required to submit their completed proposals to the GHIT Fund via Editorial Manager®. Applicants who successfully submit their proposal document will receive a confirmation email. Proposals may not be modified after the submission due date. Proposals will initially be examined to determine whether

  • The partnership meets GHIT Fund eligibility criteria
  • Project objectives are aligned with the RFP-specified scope
  • The proposal is complete and addresses all required content

External Reviewers


Each eligible proposal will be reviewed by 3 external reviewers, including experts in the discovery and development of global health technologies, each of whom possesses the experience to objectively evaluate the proposal content. External reviewers are required to declare that they have no relation to the applicants and use a proposal evaluation tool to consistently assess the quality of proposals. All proposals passing the preliminary examination will be evaluated and prioritized based on the following criteria:

  • Scientific and technical merit (e.g., sound approach and methodology, level of innovation, overall quality and comprehensiveness)
  • Potential Impact (e.g., how it will address a global health priority)
  • Partnership and project management (e.g., collaboration capabilities and expertise, project history and performance, risk management, budget)

Selection Committee

Interactive Interview and Request approval for funding recommendation

Based on the aggregated External Reviewer results and a subsequent evaluation by the GHIT Fund Selection Committee (SC), proposals will be ranked by evaluation score. The top-tier applicants will be invited for an interactive interview with the SC. The GHIT SC will then critique each proposal, assess the quality of each product development plan, and recommend funding to the Board.


Board of Directors

Review and approve funding recommendation

Proposals selected by the SC will be passed to the GHIT Fund Board of Directors whose members review and approve investment award decisions. The GHIT Board directs portfolio strategy and awards funding using a milestone-based approach to ensure return with minimal risk.


Management Team and Product Development Partners

Award Notification, Investment Agreement and Investment

The GHIT Fund will notify applicants of their selection status by email. If the proposal is selected and the applicant receives an award notification, they are required to sign the Investment Agreement with the GHIT Fund and also submit a collaboration partners contractual agreement which clearly defines the roles and responsibilities of all collaboration partners, within one month from award notification. Please be aware that the award may be void if this condition is not met. Applicants are required to identify the designated development partner (investment recipient) and all other collaboration partners. The designated development partner will be responsible for the performance of all its collaborating partners. A representative of the designated development partner will serve as the main GHIT Fund point of contact and will be responsible for all GHIT Fund discussions and negotiations.


Management Team

Initiation of Monitoring and Evaluation

Once the agreement enters into effect, the GHIT Management Team will initiate Monitoring and Evaluation process. The data and information regarding the project will be put into the system.


Management Team and Product Development Partners

Monitoring and Evaluation

To track the progress of each project, GHIT conducts progress updates twice a year. This enables us to keep track of the progress of investments and decide on whether to continue, modify, or terminate the investment contingent upon milestone achievement. With this system, data pertaining to the progress of each project is gathered via an electronic system and the GHIT Management Team holds a conference with all product development partners based on the collected data prior to the meeting.